Home > Oncology > ASCO 2021 > Breast Cancer > Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation

Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation

Presented By
Prof. Andrew Tutt , Institute of Cancer Research, UK
Conference
ASCO 2021
Trial
OlympiA
A first interim analysis of the OlympiA trial demonstrated significantly improved invasive disease-free survival in patients with high-risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant treatment with the PARP inhibitor olaparib. The PARP inhibitor olaparib is licensed for metastatic HER2-negative breast cancer with BRCA1/2 germline mutation (gBRCAm). Even with (neo)adjuvant chemotherapy, recurrence rates in patients with gBRCAm early breast cancer can be high, and novel adjuvant treatments are needed. The OlympiA trial (NCT02032823) explores the efficacy and safety of adjuvant treatment with olaparib in patients with gBRCAm, high-risk, HER2-negative primary breast cancer. The study enrolled 1,836 patients with gBRCAm and HER2-negative (triple-negative or HR-po...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on